

IN THE CLAIMS

Amend the claims as follows.

1. (Previously Amended) A method of preparing a medicament for treating oedema comprising admixing a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵ with a pharmaceutically acceptable carrier.

Claims 2-9 (Canceled).

10. (Previously Amended) A pharmaceutical composition for treating oedema comprising a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵ and a pharmaceutically acceptable carrier.

Claims 11-18 (Canceled).

19. (Currently Amended) A method of treating oedema comprising administering a composition to a person in need of said treatment, said composition being a pharmaceutical composition for treating oedema comprising a peptide chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵, and a pharmaceutically acceptable carrier, said administering resulting in treatment of said oedema.

20. (Currently Amended) A method of inducing oedema resorption comprising administering a composition to a person suffering from oedema, said composition being a pharmaceutical composition for treating oedema comprising a peptide chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵, and a pharmaceutically acceptable carrier, said administering resulting in treatment of said oedema.

21. (Previously Added) A method of claim 19 or 20, wherein said peptide comprises a chain of 11 to 16 contiguous amino acids.

22. (Previously Added) A method of claim 19 or 20, wherein said peptide comprises a chain of 13 to 15 contiguous amino acids.

23. (Previously Added) A method of claim 19 or 20, wherein said peptide comprises a chain of 14 contiguous amino acids.

24. (Previously Added) A method of claim 23, wherein said chain of 14 contiguous amino acids are chosen from the group consisting of the contiguous amino acid sequences

QRETPEGAEAKPWY (SEQ ID NO:1) and PKDTPEGAEALKPWY (SEQ ID NO:2).

25. (Previously Added) A method of claim 19 or 20, wherein said peptide is

circularized.

26. (Previously Added) A method of claim 25, wherein said peptide is circularized by replacing the NH₂- and COOH-terminal amino acids by cysteine so that a disulfide bridge is formed between the latter cysteines.

27. (Previously Added) A method of claim 26, wherein said circularized peptides are chosen from the group consisting of the circularized peptides CGQRETPEGAEAKPWYC (SEQ ID NO:4) and CGPKDTPEGAEAKPWYC (SEQ ID NO:5).

28. (Previously Added) A method of claim 19 or 20, wherein said oedema is pulmonary oedema.